For the US Food and Drug Administration, the dog days of summer came late. The highlight of a sleepy week in drug approvals was a new orphan indication for GlaxoSmithKline plc’s Nucala (mepolizumab).
On the submission front, Bristol Myers Squibb Company and bluebird bio had good news to report on the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?